demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
anti-inflammatory therapies
anti GM-CSF
mavrilimumab MASH-COVID ...
clarithromycine Rashad ...
colchicine GRECCO-19 Horby COLCOVID Salehzadeh RECOVERY ... COL-COVID ...
Colchicine plus rosuvastatin Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs
Indomethacin Ravichandran
stem cells Carmenate ... Lanzoni Shu Shi

13 studies excluded by filtering options 0

5093 PANAMO, 0 010selection pending
5423 Jeong, 2020 1150not a RCTrisk of bias not avaialble
5510 Malgorzata, 2020 1134not a RCThigh risk of bias
5555 Scarsi, 2020 1130not a RCTrisk of bias not avaialble
5594 Lopes MIF, 2020 113high risk of bias
6007 COLCHIVID, 2021 110risk of bias not avaialble
6188 Bruce, 2020 1100not a RCTrisk of bias not avaialble
6691 Tsiakos, 2020 1313not a RCThigh risk of bias
6960 Imam, 2020 1130not a RCTrisk of bias not avaialble
7011 Drake, 2021 1100not a RCTrisk of bias not avaialble
9250 Guzman-Esquivel, 2022 000selection pending
9868 Brunetti, 2020 1110not a RCTrisk of bias not avaialble
9869 Sandhu, 2020 1100not a RCTrisk of bias not avaialble